Brief: Clovis Oncology Presents Data From Triton3 Phase 3 Trial Of Rubraca® (Rucaparib) At The 29Th Annual Prostate Cancer Foundation Scientific Retreat
27/10/2022 22:48
Oct 27 (Reuters) - Clovis Oncology Inc CLVS.O :
* CLOVIS ONCOLOGY PRESENTS DATA FROM TRITON3 PHASE 3 TRIAL
OF
RUBRACA® (RUCAPARIB) AT THE 29TH ANNUAL PROSTATE CANCER
FOUNDATION SCIENTIFIC RETREAT
Source text for Eikon: ID:nBw4jYLhja
Further company coverage: CLVS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clovis Oncology
See all newsBrief: Clovis Oncology Inc - On April 5, 2023, Entered Into Asset Purchase Agreement With Pharma& To Sell Product Business For Upfront Payment Of $70 Million
Brief: Clovis Oncology Enters Into Financing Agreement
Brief: Clovis Oncology Inc Received Written Notice From Nasdaq That Company's Common Stock Will Be Delisted From Nasdaq
U.S. STOCKS ON THE MOVE-Nike, Faraday Future, PBF Energy
U.S. STOCKS ON THE MOVE-Natural gas, Box Inc, Weber